Interestingly, we found that tumors from patients with MM with germline BAP1 mutations displayed a significantly higher expression level of CCL2 compared with that in tumors from sporadic MM cases without germline BAP1 mutations (P = 0.043; Fig. 7A). This evidence concerns the gene BAP1 and Miyoshi myopathy.